Ivonescimab versus pembrolizumab in PD-L1-positive NSCLC

Mingyang Xue; Wenyi Jin

doi:10.1016/S0140-6736(25)01236-X

Ivonescimab versus pembrolizumab in PD-L1-positive NSCLC

Mingyang Xue
, Wenyi Jin^*

^*Corresponding author for this work

Department of Biomedical Sciences

Research output: Journal Publications and Reviews › Letter

1 Citation (Scopus)

Original language	English
Pages (from-to)	1336-1337
Number of pages	2
Journal	The Lancet
Volume	406
Issue number	10510
Online published	25 Sept 2025
DOIs	https://doi.org/10.1016/S0140-6736(25)01236-X
Publication status	Published - 27 Sept 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access Output

10.1016/S0140-6736(25)01236-X

Other Access Options

Check CityUHK Library

Permanent Link

Right click to copy link

Cite this

@article{9850f3d0a0974720b7375539b487182b,

title = "Ivonescimab versus pembrolizumab in PD-L1-positive NSCLC",

author = "Mingyang Xue and Wenyi Jin",

year = "2025",

month = sep,

day = "27",

doi = "10.1016/S0140-6736(25)01236-X",

language = "English",

volume = "406",

pages = "1336--1337",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "10510",

}

TY - JOUR

T1 - Ivonescimab versus pembrolizumab in PD-L1-positive NSCLC

AU - Xue, Mingyang

AU - Jin, Wenyi

PY - 2025/9/27

Y1 - 2025/9/27

UR - https://www.scopus.com/pages/publications/105016794222

UR - https://www.scopus.com/record/pubmetrics.uri?eid=2-s2.0-105016794222&origin=recordpage

U2 - 10.1016/S0140-6736(25)01236-X

DO - 10.1016/S0140-6736(25)01236-X

M3 - Letter

C2 - 41015516

SN - 0140-6736

VL - 406

SP - 1336

EP - 1337

JO - The Lancet

JF - The Lancet

IS - 10510

ER -

Ivonescimab versus pembrolizumab in PD-L1-positive NSCLC

UN SDGs

Access Output

Other Access Options

Permanent Link

Other Files and Links

Cite this